Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Catalyst to Continue Testing Vigabatrin

By Drug Discovery Trends Editor | October 2, 2009

NEW YORK (AP) – Catalyst Pharmaceutical Partners Inc. says it will continue developing an anti-addiction drug that has failed in two clinical trials, as it believes the treatment is safe and effective.

Catalyst said its drug vigabatrin failed as a treatment for cocaine addiction because patients in the trial did not take the drug regularly. Based on analysis of results from patients who did take vigabatrin regularly, Catalyst said late Wednesday that there is evidence the drug works, and is safe. However it also said the drug failed against methamphetamine addiction.

Shares of the Coral Gables, Fla., company climbed 50 cents, or 60 percent, to $1.35, after earlier doubling. The shares have traded between 39 cents and $2.95 over the last year, and plunged in May after Catalyst reported unsuccessful results from the cocaine trial.

The company said it has analyzed patients’ urine from the cocaine study, and found that less than 40 percent of patients were taking vigabatrin as often as they were supposed to. Catalyst said an independent panel of experts agreed with its view that there is enough evidence to continue testing the drug because it increased abstinence from cocaine and reduced use, along with reducing the number of days the patients used cocaine.

The trial was designed with the assumption that 85 percent of the patients would take the drug as scheduled.

Catalyst reported results from the methamphetamine study on Thursday. It said patients who took vigabatrin were 2.5 times more likely to stay off the drug in the last two weeks of the 12-week study. That was not much better than patients who were taking a placebo, but the company said it is an encouraging result.

Merriman Curhan Ford analyst Edward Nash said Catalyst addressed the reasons for the failure of the cocaine study, and he now thinks the company has a chance to develop vigabatrin successfully. He upgraded the shares to “Neutral” from “Sell.”

“We believe this creates a light at the end of the tunnel for Catalyst,” Nash said in a note to clients.

French drugmaker Sanofi-Aventis markets vigabatrin overseas under the name Sabril.

Date: October 1, 2009
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE